Research April 2026

KRAS G12D tumors: setidegrasib and zoldonrasib may change the targeted therapy landscape

A potentially transformative therapy is emerging in oncology for tumors with the KRAS G12D mutation. This mutation has been considered one of the most difficult drug targets for decades, particularly in pancreatic cancer. Two approaches now look particularly important — degradation of the mutant KRAS protein with setidegrasib, and selective inhibition of KRAS G12D with zoldonrasib. Both drugs remain in clinical development and are not yet routine standard of care, but the approach looks very promising.

Key points

Astellas announced that the first patient has been dosed in the Phase 3 registrational study of setidegrasib for KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma. In this trial, setidegrasib is evaluated in the first line in combination with mFOLFIRINOX or NALIRIFOX, with more than 600 patients planned for enrollment.
In Phase 1, setidegrasib demonstrated objective responses in 36% of patients with KRAS G12D-mutated non-small cell lung cancer and in 24% of patients with pancreatic ductal adenocarcinoma at the selected dose.
Revolution Medicines announced that the FDA has granted zoldonrasib Breakthrough Therapy Designation for KRAS G12D-mutated non-small cell lung cancer.

Key study numbers

Setidegrasib was studied in Phase 1 in patients with advanced KRAS G12D-mutated tumors, including NSCLC and pancreatic ductal adenocarcinoma. At the 600 mg dose, objective response was observed in 36% of NSCLC patients, with median progression-free survival of 8.3 months. In patients with pancreatic ductal adenocarcinoma receiving the drug in the second or third line, objective response rate was 24%, median PFS 3.0 months, and median overall survival 10.3 months.

Another important point for pancreatic cancer: the KRAS G12D mutation occurs in approximately 40% of patients, yet no targeted therapy specifically directed against KRAS G12D currently exists. This is why setidegrasib’s transition into a Phase 3 registrational trial for metastatic pancreatic cancer is a fundamentally important event.

Why this matters for practice

KRAS has long been a symbol of a difficult mutation. Initially it seemed almost impossible to target directly; then drugs for KRAS G12C appeared, but KRAS G12D remained a much harder target. This is particularly important for pancreatic cancer, where KRAS mutations are very common and KRAS G12D is one of the most prevalent variants.

Two distinct approaches are now emerging. The first is not simply blocking mutant KRAS but directing the protein toward destruction — this is the mechanism of setidegrasib, a selective KRAS G12D degrader. The second is selectively inhibiting the active form of KRAS G12D — the mechanism of zoldonrasib, which received FDA Breakthrough Therapy Designation for KRAS G12D-mutated NSCLC.

Limitations — what does not change yet

This does not mean that setidegrasib or zoldonrasib have become the standard of care. Setidegrasib has only just entered the Phase 3 registrational trial for metastatic pancreatic cancer, and Phase 1 data remain early. Astellas specifically notes that the safety and efficacy of setidegrasib for the uses under investigation have not been established and regulatory approval is not guaranteed.

Zoldonrasib also remains an investigational drug. Breakthrough Therapy status does not equal registration and does not mean the drug is already available as standard treatment. This designation indicates that the FDA recognizes a significant unmet need and preliminary clinical data that warrant expedited development.

Commentary by Evgeny Ledin

For clinical practice this means that molecular genetic testing in pancreatic cancer, lung cancer, and other common tumors is becoming increasingly important. If the KRAS G12D mutation was previously often perceived as merely an interesting finding, it is now gradually becoming a potentially clinically meaningful biomarker.

This news matters most to patients with pancreatic ductal adenocarcinoma, non-small cell lung cancer, and other common tumors in whom the KRAS G12D mutation has been identified — and especially to patients whose disease already requires systemic therapy and who are asking whether, beyond standard chemotherapy or immunotherapy, there are other molecularly-directed treatment options.

For now this news does not change treatment standards, but it is very important in perspective. If a patient with pancreatic or lung cancer has had full molecular testing and KRAS G12D was identified, this may become a potential entry point into a clinical trial or into a future targeted strategy.

Conclusion

The KRAS G12D mutation is ceasing to be a theoretical mutation and is gradually becoming a real target in clinical work. It is important to perform molecular genetic testing in time and to understand which new investigational options may be practically applicable to the specific patient.

When a second opinion is especially helpful

you have pancreatic cancer, lung cancer, or another common tumor, but molecular testing has not yet been performed;
KRAS G12D mutation has been identified in the molecular report, but it is unclear how this changes your treatment plan;
standard treatment options are already limited, and you want to understand whether there are suitable clinical trials;
treatment is being proposed without discussing the tumor’s molecular profile;
you want to understand where standard therapy ends and the investigational path begins.

What to prepare for the consultation

histology report;
results of molecular testing, including KRAS;
records of all prior treatment lines;
CT, MRI, or PET-CT scans with serial imaging;
information about current general status and symptoms;
list of comorbidities and current medications;
if molecular testing has not been performed — tumor blocks or slides if available.

Source: Astellas: Phase 3 Study of setidegrasib for KRAS G12D Pancreatic Adenocarcinoma; PubMed: Setidegrasib in NSCLC and Pancreatic Cancer; Revolution Medicines: FDA Breakthrough Therapy for zoldonrasib.

Frequently asked questions

Does this news apply to all pancreatic cancer patients?

No. This concerns patients whose tumors carry the KRAS G12D mutation specifically. Even in such cases, setidegrasib remains an investigational drug and is not standard of care.

Why is the KRAS G12D mutation so important in pancreatic cancer?

KRAS G12D occurs in approximately 40% of patients with pancreatic ductal adenocarcinoma. Until now there has been no approved targeted therapy for this mutation, which is why the emergence of drugs directed against KRAS G12D is highly significant.

How does setidegrasib differ from a conventional inhibitor?

Setidegrasib is a KRAS G12D protein degrader. Its task is not simply to block the signal but to direct the mutant protein toward destruction. This is a fundamentally different approach to targeting KRAS.

What does Breakthrough Therapy status mean for zoldonrasib?

This is an FDA designation that can accelerate the development and review of a drug in serious conditions with high unmet need. However, it is not registration and does not mean the drug has become standard of care.